Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/181261LACTOFERRIN FOR ORAL INHALATION USE FOR THE TREATMENT OF A DISEASE CAUSED BY A SARS-CORONA VIRUS
WO 16.09.2021
Int.Class A61K 38/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
40Transferrins, e.g. lactoferrins, ovotransferrins
Appl.No PCT/IB2021/051941 Applicant SOFAR S.P.A. Inventor BIFFI, Andrea
The present invention relates to a composition comprising lactoferrin for inhalation use in the treatment of viral infections of the respiratory system, and related symptoms or disorders, caused by a SARS- coronavirus (e.g. COVID-19 disease). In addition, the present invention relates to a device for the administration - through the inhalation route - of said composition comprising lactoferrin and the use thereof in said methods for the treatment of viral infections.
2.3892274NICOTINE FOR THE PREVENTION AND TREATMENT OF COVID-19 DISEASE
EP 13.10.2021
Int.Class A61K 31/465
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
465Nicotine; Derivatives thereof
Appl.No 20315125 Applicant HOPITAUX PARIS ASSIST PUBLIQUE Inventor MIYARA MAKOTO
The invention relates to nicotine or a pharmaceutical salt thereof for use for preventing and/or treating viral infections due to at least one betacoronavirus, preferably a Severe Acute Respiratory Syndrome-related coronavirus.
3.WO/2021/175250COMPOUNDS AND METHODS FOR TREATING DISEASES AND/OR CONDITIONS CAUSED BY CORONAVIRUS
WO 10.09.2021
Int.Class A61K 31/43
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
429condensed with heterocyclic ring systems
43Compounds containing 4-thia-1-azabicyclo heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
Appl.No PCT/CN2021/078875 Applicant APTORUM THERAPEUTICS LIMITED Inventor LEE, Wai Yip Thomas
Compounds and compositions, for example vardenafil, for treating diseases and/or conditions caused by, arising from, and/or associated with coronavirus in a subject, for example a subject infected with SARS-CoV-2 or other coronavirus. Combinations of agents useful for treating diseases and/or conditions caused by, arising from, and/or associated with coronavirus in a subject, for example, vardenafil and Remdesivir, are also provided.
4.3884946COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION
EP 29.09.2021
Int.Class A61K 31/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
Appl.No 20305327 Applicant ABIVAX Inventor TAZI JAMAL
COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURENCE OF A CORONAVIRIDAE INFECTION
5.WO/2021/158248METHOD FOR TREATING CORONAVIRUS INFECTIONS
WO 12.08.2021
Int.Class A61K 31/473
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
473ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
Appl.No PCT/US2020/028567 Applicant OYAGEN, INC. Inventor SMITH, Harold, C.
Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
6.WO/2021/204814NACHR, SUCH AS NICOTINE, FOR USE IN THE PREVENTION AND THE TREATMENT OF COVID-19 DISEASE
WO 14.10.2021
Int.Class A61K 31/465
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
465Nicotine; Derivatives thereof
Appl.No PCT/EP2021/058960 Applicant ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS Inventor MIYARA, Makoto
The invention relates to a ligand having a modulatory effect on neuronal nicotinic acetylcholine receptor (nAChR) or a pharmaceutical salt thereof for use for preventing and/or treating viral infections due to at least one betacoronavirus, preferably a Severe Acute Respiratory Syndrome-related coronavirus.
7.3892269PROBENECID FOR TREATING CORONAVIRUS INFECTIONS
EP 13.10.2021
Int.Class A61K 31/195
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
Appl.No 20202059 Applicant UNIV GEORGIA Inventor TRIPP RALPH A
Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.
8.WO/2021/173592SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF
WO 02.09.2021
Int.Class A61K 31/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
34having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
Appl.No PCT/US2021/019295 Applicant MEMORIAL SLOAN-KETTERING CANCER CENTER Inventor WENDEL, Hans-Guido
Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses (e.g., severe acute respiratory syndrome coronavirus [SARS-CoV], severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2, the virus and its mutant forms that cause COVID-19], Middle East respiratory syndrome coronavirus [MERS-CoV]), Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.
9.WO/2021/158701METHOD FOR TREATING CORONAVIRUS INFECTIONS
WO 12.08.2021
Int.Class A61K 31/706
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
Appl.No PCT/US2021/016472 Applicant OYAGEN, INC. Inventor SMITH, Harold, C.
Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections and SARS-CoV-2 infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
10.3892275AEROSOLIZATION OF HCQ OR ITS METABOLITES FOR THE TREATMENT OF LUNG INFECTIONS
EP 13.10.2021
Int.Class A61K 31/4706
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
Appl.No 20315131 Applicant INST NAT SANTE RECH MED Inventor
Coronaviruses cause severe diseases mainly of the respiratory and gastrointestinal tract. The infection of humans with coronaviruses have been known since the sixties to be associated with respiratory tract i.e. common cold-like diseases. Severe Acute Respiratory Syndrome-Corona Virus (SARS-CoV) is a highly aggressive in humans with often fatal outcome. The inventors aim at developing a new prophylactic or preventive therapeutic approach as well as a curative therapeutic approach based on the local delivery of hydroxychloroquine (HCQ) or its metabolite (e.g. Desethylhydroxychloroquine (DHCQ)) into the lung by aerosolization. The present invention relates to a method of treating Severe Acute Respiratory Syndrome-Corona Virus (SARS-CoV) in a patient in need thereof comprising administering to the patient's lungs a therapeutically effective amount of hydroxychloroquine (HCQ) and/or Desethylhydroxychloroquine (DHCQ) by aerosolization.